Nurix Therapeutics, Inc.
US ˙ NasdaqGM ˙ US67080M1036

SecurityNRIX / Nurix Therapeutics, Inc.
InstitutionExodusPoint Capital Management, LP
Latest Disclosed Ownership62,503 shares
Latest Disclosed Value $ 968,796
ExodusPoint Capital Management, LP reports 51.97% decrease in ownership of NRIX / Nurix Therapeutics, Inc.

On May 14, 2026 - ExodusPoint Capital Management, LP filed a 13F-HR form disclosing ownership of 62,503 shares of Nurix Therapeutics, Inc. (US:NRIX) valued at $968,796 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2025 disclosing 130,130 shares of Nurix Therapeutics, Inc.. This represents a change in shares of -51.97% during the quarter. The current value of the position is $915,044 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F NURIX THERAPEUTICS COM 67080M103 62,503 -67,627 -51.97 969 -19.47 0.0078
2025-11-14 2025-09-30 13F NURIX THERAPEUTICS COM 67080M103 130,130 -63,364 -32.75 1,202 60,000.00 0.0123
2025-08-13 2025-06-30 13F NURIX THERAPEUTICS COM 67080M103 193,494 174,326 909.46 2 0.0193
2025-05-14 2025-03-31 13F NURIX THERAPEUTICS COM 67080M103 19,168 -66,494 -77.62 0 -100.00 0.0023
2025-02-12 2024-12-31 13F NURIX THERAPEUTICS COM 67080M103 85,662 51,049 147.49 2 0.0111
2024-11-12 2024-09-30 13F NURIX THERAPEUTICS COM 67080M103 34,613 -285,939 -89.20 1 -100.00 0.0047
2024-08-13 2024-06-30 13F NURIX THERAPEUTICS COM 67080M103 320,552 154,949 93.57 7 200.00 0.0456
2024-05-14 2024-03-31 13F NURIX THERAPEUTICS COM 67080M103 165,603 -132,166 -44.39 2 -33.33 0.0186
2024-02-14 2023-12-31 13F NURIX THERAPEUTICS COM 67080M103 297,769 247,621 493.78 3 0.0202
2023-11-13 2023-09-30 13F NURIX THERAPEUTICS COM 67080M103 50,148 8,430 20.21 0 0.0038
2023-08-11 2023-06-30 13F NURIX THERAPEUTICS COM 67080M103 41,718 41,718 0 0.0034
2023-02-13 2022-12-31 13F NURIX THERAPEUTICS COM 67080M103 0 -25,954 -100.00 0 -100.00
2022-11-10 2022-09-30 13F NURIX THERAPEUTICS COM 67080M103 25,954 25,954 338 0.0044
2022-08-20 2022-06-30 13F NURIX THERAPEUTICS COM 67080M103 0 -15,034 -100.00 0 -100.00
2022-05-13 2022-03-31 13F NURIX THERAPEUTICS COM 67080M103 15,034 15,034 211 0.0027
2022-02-11 2021-12-31 13F NURIX THERAPEUTICS COM 67080M103 0 -10,747 -100.00 0 -100.00
2021-11-15 2021-09-30 13F NURIX THERAPEUTICS COM 67080M103 10,747 10,747 322 0.0043
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.